Moxetumomab pasudotox in relapsed/refractory hairy cell leukemiaRobert J. Kreitman, Francis J. Giles, Douglas E. Gladstone et al.|Leukemia|2018Cited by 250
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironmentElizabeth Hardaker, Steven Fawell, Emilio Sanseviero et al.|Nature Communications|2024Cited by 62
Abstract CT198: Immunomodulatory effects of the ATR inhibitor ceralasertib in a window of opportunity biomarker trial in patients with head and neck squamous cell carcinomaGemma N. Jones, Umamaheswar Duvvuri, Sonia Iyer et al.|Cancer Research|2023Cited by 3